PL BioScience Launches World's Only Patented Gamma-irradiated Human Platelet Lysate
AACHEN, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced the launch of ELAREM™ Ultimate-FD PLUS, the only gamma-irradiated, GMP-grade Human Platelet Lysate produced in Germany using a globally patented process. With the increasing demand for safe, xeno-free, ethically sourced cell culture supplements in cell therapy, regenerative medicine, and biopharmaceutical manufacturing, ELAREM™ Ultimate-FD PLUS answers a critical industry need: a virus-inactivated, animal-free, and EU-manufactured alternative that meets the highest quality standards.
'We are thrilled to bring the only gamma-irradiated Human Platelet Lysate produced in Europe to the dynamic field of cell and gene therapy,' said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. 'This product isn't just a milestone for Europe – it's a globally unique offering. With comprehensive patent protection and fully EU-based production, ELAREM™ Ultimate-FD PLUS ensures a stable supply chain and offers global manufacturers a high-quality, regulatory-ready solution that meets the highest international standards.'
Cell culture supplements are essential for growing cells in the laboratory. They play a critical role in the development and manufacturing of advanced therapies like cell and gene therapies. Traditionally, these supplements often contain components derived from other species, such as fetal bovine serum (FBS). These animal-derived products carry potential safety risks, for example bacterial or viral contamination, and pose ethical concerns. HPL offers a fully human-derived, xeno-free alternative that is safe, consistent, and sustainable.
ELAREM™ Ultimate-FD PLUS takes this one step further. Through a proprietary gamma-irradiation process, the product undergoes viral inactivation to add an extra layer of safety and regulatory assurance. The gamma-irradiated, xeno-free, fibrinogen-depleted, and anticoagulant-free product complies with the relevant GMP (Good Manufacturing Practice) guidelines. This makes it especially suitable for cell manufacturing applications where viral reduction is critical, such as potential use in clinical trials.
About Human Platelet Lysate:
Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable and resource-efficient alternative to traditional cell culture supplements.
In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices.
ELAREM™, PL BioScience's line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: https://www.pl-bioscience.com/
Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
[email protected]
Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0
US: Catherine Featherston
+1-203-444-4393
E-Mail: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"
BOSTON, June 10, 2025 /PRNewswire/ -- NanoHive Medical, LLC, a leading innovative 3D printed spinal implant technology company is pleased to announce that the company has secured the exclusive sublicense of DirectSync Surgical's piezoelectric implantable sensor technology for the field of spinal fusion. DirectSync Surgical had licensed the technology from the University of Kansas. NanoHive is exploring the advancement of successful proof-of-concept research to potentially develop bone stimulating and remote monitoring/data collection sensor technology housed in the company's highly innovative spinal interbody fusion device lattice which is currently commercialized in the company's Hive™ Soft Titanium® portfolio of 3D printed spinal interbody fusion devices. In October 2023, the company reported the initiation of a research collaboration with DirectSync Surgical. Based on the preliminary research generated, the company ascertained that their proprietary rhombic dodecahedron lattice technology was uniquely capable of transferring significant energy from the encapsulated piezoelectric sensor. The company is currently in the process of working with the US Food and Drug Administration (FDA) on the transfer of the Breakthrough Device Designation from DirectSync to NanoHive. Patrick O'Donnell, President & CEO of NanoHive stated, "NanoHive's Soft Titanium® technology is the ideal interbody fusion implant to deliver a sensor with data collection and bone stimulation capability. The company is excited about the prospect of leading the way with the development of a technological leap in the interbody fusion device category. Our view of the future of innovation in spine devices emphasizes that new technologies must demonstrate an improvement to patient virtual care and clinical outcomes as well as connectivity with enabling surgical technologies and artificial intelligence. These advancements must also deliver cost-efficiencies to the various stakeholders involved in the spine patient's episode-of-care. More meaningful and frequent data collection that can ultimately be utilized as a predictive tool will be essential to this vision." About NanoHive Medical LLC NanoHive Medical is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company's proprietary, biomimetic Soft Titanium® technology clearly distinguishes their products in the $2.4B U.S. spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences. NanoHive Medical is based in Woburn, Massachusetts U.S.A. Contact: Patrick O'Donnell, CEO & President, NanoHive Medical LLC, Website: About DirectSync Surgical DirectSync Surgical is a rising leader in smart patient powered implant devices. With a commitment to innovation and foundational research, the company develops and manufactures advanced tools that empower both spinal and orthopedic professionals to achieve superior surgical outcomes. DirectSync Surgical's products are not available for sale in the US. Contact: Leighton LaPierre, COO, DirectSync Surgical, leighton@ Website: NanoHive Medical, LLC | 12 Gill Street, Suite 4500 | Woburn, MA 01801 | 844-943-5433 View original content to download multimedia: SOURCE NanoHive Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Atomic Capital Supports Strategic Sale of UFirst, a Top Russian Children's Education Network
Atomic Capital acted as exclusive financial adviser in the successful sale of 100% of UFirst, a prominent operator in the Russian children's education sector. Moscow, Russia, June 10, 2025 (GLOBE NEWSWIRE) -- Atomic Capital acted as exclusive financial adviser in the successful sale of 100% of UFirst, a prominent operator in the Russian children's education sector. UFirst, formerly part of the international education group English First (EF), was subsequently acquired and developed by its management team. Today, the network includes 15 learning centers located in Moscow, St. Petersburg, and Novosibirsk, offering a diverse range of programs such as English and Chinese language courses, programming, exam readiness, and MBA pathways tailored for children and teenagers. The Russian market continues to show significant investment interest among international businesses. Despite the current global challenges, Russia remains one of the most attractive locations for foreign investors and strategic partners, offering distinctive opportunities for business expansion, new project development, and effective capital deployment. Atomic Capital possesses deep experience and expertise in supporting sophisticated deals with the involvement of international companies, representing both buyers and sellers. The company assists clients in entering or exiting the Russian market, helps refine entry and exit strategies, and provides end-to-end financial and legal advisory throughout every phase of the deal, ensuring transparency and operational efficiency. Atomic Capital frequently collaborates with international firms—those aiming to establish or grow their presence in Russia, as well as those evaluating the sale of Russian assets. The company offers dedicated support at every step and is committed to securing optimal results for all participants. 'We are convinced that the role of a professional financial adviser in M&A extends well beyond the deal itself—it is about delivering long-term value for every stakeholder. We appreciate all parties for their high level of cooperation and professionalism. This project reflects coordinated teamwork and mutual trust,' commented Alexander Zaitsev, CEO of Atomic Capital. Atomic Capital welcomes companies from across the globe to work together in the Russian market, guaranteeing an individualized approach, transparency, and a consistently high level of service for every engagement. Irina Ayatova, Atomic Capitalpress@ (495) 488 66 33
Yahoo
21 minutes ago
- Yahoo
Titanium Transportation Announces Voting Results of Annual General Meeting of Shareholders
BOLTON, Ontario, June 10, 2025 (GLOBE NEWSWIRE) -- Titanium Transportation Group Inc. ("Titanium" or the "Company") (TSX:TTNM, OTCQX:TTNMF), a leading provider of transportation and logistics services throughout North America, is pleased to announce that all of the nominees listed in the Company's Management Information Circular for the Annual General Meeting of Shareholders held on June 9, 2025 (the 'Meeting') were elected to the Board of Directors. Each director will serve until the next annual meeting of shareholders or until their successors are elected or appointed or they otherwise cease to serve as directors. Detailed results of the vote for the election of directors held at the meeting are set out below: Nominee Votes in Favor % Votes Withheld % Ted Daniel 23,970,752 99.93% 17,111 0.07% Lu Galasso 23,934,523 99.78% 53,340 0.22% Bill Chyfetz 21,801,241 90.88% 2,186,622 9.12% David Bradley 21,920,983 90.87% 2,166,970 9.03% Grace Palombo 21,822,494 90.97% 2,165,369 9.03% A total of 24,039,029 shares were represented at the Meeting, representing 52.91% of the issued and outstanding common shares of the Company as at the record date. At the Meeting, shareholders also approved the reappointment of KPMG LLP as the Company's independent auditor for 2025. About Titanium Titanium is a leading North American transportation company with asset-based trucking operations and logistics brokerages servicing Canada and the United States, with approximately 850 power units, 3,000 trailers and 1,300 employees and independent owner operators. Titanium provides truckload, dedicated, and cross-border trucking services, logistics, and warehousing and distribution to over 1,000 customers. Titanium has established both asset-based and brokerage operations in Canada and the U.S. with eighteen (18) locations. Titanium is a recognized purchaser of asset-based trucking companies, having completed thirteen (13) transactions since 2011. Titanium ranked among top 500 companies in the inaugural Financial Times Americas' Fastest Growing Companies in 2020. The Company was ranked by Canadian Business as one of Canada's Fastest Growing Companies for eleven (11) consecutive years. For four (4) consecutive years, Titanium has also been ranked one of Canada's Top Growing Companies by the Globe and Mail's Report on Business of Canada. Titanium is listed on the Toronto Stock Exchange under the symbol 'TTNM" and 'TTNMF' on the statements contained in this press release constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking statements are provided for the purposes of assisting the reader in understanding Titanium's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information may relate to Titanium's future outlook and anticipated events, and may include statements regarding the financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives of or involving Titanium. Particularly, statements regarding future acquisitions, the availability of credit, performance, achievements, prospects or opportunities for Titanium or the industry in which it operates are forward-looking statements. In some cases, forward-looking information can be identified by terms such as "may", "might", "will", "could", "should", "would", "occur", "expect", "plan", "anticipate", "believe", "intend", "seek", "aim", "estimate", "target", "project", "predict", "forecast", "potential", "continue", "likely", "schedule", or the negative thereof or other similar expressions concerning matters that are not historical facts. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While management considers these assumptions to be reasonable based on currently available information, they may prove to be incorrect. The forward-looking statements made in this press release are dated, and relate only to events or information, as of the date of this press release. Except as specifically required by law, Titanium undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. CONTACT INFORMATION Titanium Transportation Group Inc. Ted Daniel, CPA, CA Chief Executive Officer (905) 266-3011 For Investors RelationsJames in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
